<DOC>
	<DOCNO>NCT02485769</DOCNO>
	<brief_summary>A Phase 1 , Randomized , Double Blind , Sponsor Open , Placebo Controlled , Sequential Group , Multiple Ascending Dose Escalation Study To Evaluate The Safety , Tolerability , And Pharmacokinetics Of Orally Administered PF-06650833 In Healthy Subjects</brief_summary>
	<brief_title>Study To Evaluate The Safety , Tolerability , And Pharmacokinetics Of Oral Pf-06650833 In Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>1 . Healthy female subject non childbearing potential and/or male subject , time screening , age 18 55 year , inclusive . 2 . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . 3 . Evidence personally sign date informed consent document indicate subject inform pertinent aspect study . 4 . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . 1 . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . 2 . Any condition possibly affect drug absorption ( eg , gastrectomy ) . 3 . A positive urine drug screen . 4 . History regular alcohol consumption exceed 7 drinks/week female 14 drinks/week male ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month Screening . 5 . Smokers must exceed equivalent 5 cigarette per day . 6 . Treatment investigational drug within 30 day ( determined local requirement ) 5 half life precede first dose investigational product ( whichever longer ) . 7 . Screening supine blood pressure100 mm Hg ( systolic ) 50 mm Hg ( diastolic ) ; 140 mm Hg ( systolic ) 90 mm Hg ( diastolic ) follow least 5 minute supine rest . If blood pressure ( BP ) 40 mm Hg ( systolic ) 90 mm Hg ( diastolic ) , BP repeat two time average three BP value use determine subject 's eligibility . 8 . Screening pulse heart rate ( HR ) &gt; 100 bpm least 5 minute rest . If pulse/HR &gt; 100 bpm , pulse/HR repeat two time ( separate least 2 minute ) average three pulse/HR value use determine subject 's eligibility . 9 . Screening 12 lead ECG demonstrate QTc &gt; 450 msec QRS interval &gt; 120 msec . If QTc exceed 450 msec , QRS exceed 120 msec , ECG repeat two time average three QTc QRS value use determine subject 's eligibility . 10 . Clinically significant abnormality chest X ray perform screen within 3 month screen date . 11 . History tuberculosis active latent inadequately treated infection , positive Quantiferon TB test 12 . History hepatitis HIV , positive test human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HepBsAg ) , hepatitis B core antibody ( HepBcAb ) hepatitis C antibody ( HCVAb ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>